Nanovibronix (NASDAQ:FEED) Posts Earnings Results

Nanovibronix (NASDAQ:FEED) posted its quarterly earnings results on Monday. The company reported ($1.98) earnings per share (EPS) for the quarter, FiscalAI reports. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%. The firm had revenue of $0.24 million for the quarter.

Nanovibronix Stock Performance

Shares of Nanovibronix stock traded up $0.03 on Monday, reaching $0.46. The stock had a trading volume of 457,095 shares, compared to its average volume of 5,566,522. The stock has a market cap of $2.83 million, a P/E ratio of -0.05 and a beta of 1.39. Nanovibronix has a fifty-two week low of $0.29 and a fifty-two week high of $17.40. The business’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $1.35.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Wall Street Zen upgraded shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nanovibronix presently has a consensus rating of “Sell”.

Insider Activity at Nanovibronix

In other news, insider Christian Michael Glibert sold 210,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $0.69, for a total value of $144,900.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 12.20% of the stock is currently owned by company insiders.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.